Special Issue

Clonal Evolution in Cancer

Message from the Guest Editors

From the early steps of carcinogenesis up to the late stages of advanced malignancy, tumors undergo genetic and epigenetic changes that shape the natural history of the disease and dramatically affect therapy responses. Many cancers are initiated from a single cell affected by a combination of mutations that are sufficient and enough to drive continuous mitotic growth. However, due to chronic replication stress and inherent insufficiencies of DNA damage responses, the descendants of cancer progenitor cells tend to stochastically accumulate additional genetic and epigenetic alterations that are randomly dispersed between co-dividing cell populations. These reiterative genomic insults generate intratumor genetic heterogeneity, allowing the emergence of multiple subclones that are subjected to selection and adaptation. This Special Issue of Cancers is dedicated to presenting advances in our understanding of intratumor natural selection through comprehensive reviews and original research articles on cancer clonal evolution written by experts in the field. For further reading, please visit the Special Issue website.

Guest Editors

Dr. Sarantis Gagos

Laboratory of Genetics, Center of Clinical Research, Experimental Surgery and Translational Research Biomedical Research Foundation Academy of Athens (BRFAA), Athens, Greece

Dr. Theodoros Rampias

Biomedical Research Foundation of the Academy of Athens (BRFAA), 11741 Athens, Greece

Deadline for manuscript submissions

closed (31 March 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/122421

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)